Long-term Outcome In Patients With Recurrent Malignant Glioma Treated With Perillyl Alcohol Inhalation | 18095
Journal of Addiction Research & Therapy
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
This retrospective study aimed to evaluate long-term response and toxicity of recurrent malignant glioma patients to
inhalation chemotherapy with perillyl alcohol (POH).
Patients and methods:
The cohort included 117 men and 81 women with primary glioblastoma multiforme (GBM; n=154),
grade III astrocytoma (AA; n=26) and anaplastic oligodendroglioma (AO; n=5). POH inhalation schedule 4-times daily
started with 66.7 mg/dose; 266 mg/day and escalated up to 133.4 mg/dose; 533.6 mg/day. Clinical toxicity and overall survival
following treatment were compared with tumor size; topography; extent of peritumoral edema and histological classification.
Adhesion to the protocol was high (>95%), POH (533.6 mg/daily) occasionally caused nose soreness but rarely
nosebleed. Tumor size, peritumoral edema and oligodendroglial component influenced response to treatment.
After 4 years under exclusive POH treatment, 19% patients still remain in clinical remission. Long-term POH
inhalation chemotherapy is a safe and non-invasive strategy efficient for recurrent malignant glioma
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals